Journal
VACCINE
Volume 29, Issue 25, Pages 4264-4273Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.03.009
Keywords
Tetravalent meningococcal vaccine; Conjugate vaccine; Bactericidal activity; Hexavalent vaccine; DTaP-HBV-IPV/Hib combination vaccine
Categories
Funding
- GSK
- GlaxoSmithKline Biologicals
- GSK Biologicals
Ask authors/readers for more resources
Tetravalent meningococcal serogroups ACWY conjugate vaccines will provide an advantage to those at most risk of invasive meningococcal disease; namely young children. Co-administration of ACWY-TT with DTaP-HBV-IPV/Hib was assessed in a randomized trial in 793 children aged 12-23 months. Pre-specified criteria for non-inferiority of immunogenicity following co-administration versus separate ACWY-TT and DTaP-HBV-IPV/Hib administration were reached. One month post-vaccination, >= 97.3% of ACWY-TT vaccinees had rSBA titres >= 1:8 (all serogroups). Seroprotection/seropositivity rates against DTaP-HBV-IPV/Hib antigens were >= 98.2%. The safety profile of co-administration was similar to that of DTaP-HBV-IPV/Hib alone. ACWY-TT and DTaP-HBV-IPV/Hib co-administration during the second year would facilitate introduction of ACWY-TT into routine toddler vaccination schedules. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available